YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Resistance Mechanism of Enterococcus faecalis to LCB01-0371, a New Oxazolidinone

새로운 옥사졸리디논계 항균제 LCB01-0371에 대한 Enterococcus faecalis의 내성 기전

  • Lee, Hyun-Hee (School of Life Science, Handong Global University) ;
  • Lee, Su-Ro (School of Life Science, Handong Global University) ;
  • Kwak, Jin-Hwan (School of Life Science, Handong Global University)
  • Received : 2013.11.07
  • Accepted : 2013.12.02
  • Published : 2014.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

To study the resistance mechanism of E. faecalis to LCB01-0371, several resistant mutants to LCB01-0371 or linezolid were isolated by step-wise selection. The frequency of spontaneous mutations resistant to LCB01-0371 was lower than that of linezolid in E. faecalis. The genetic variations in resistant mutants were analyzed by DNA sequencing of domain V of 23S rRNA in each mutant. The first-step mutant to LCB01-0371 had a G2576T point mutation in V domain of 23S rRNA. However, no resistant mutant to LCB01-0371 was isolated in second-step mutant selection.

Keywords

References

  1. Michael, A. F. and Christopher, T. W. : Antibiotics for emerging pathogens. Science 325, 1089 (2009). https://doi.org/10.1126/science.1176667
  2. Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilber, D., Rice, L. B., Scheld, M., Spellberg, B. and Bartlett, J. : Bad bugs, no drugs : no ESKAPE! An update from the infectious diseases society of America. Clin. Infect. Dis. 48, 1 (2009). https://doi.org/10.1086/595011
  3. Rybak, J. M., Barber, K. E. and Rybak, M. J. : Current and prospective treatments for multidrug-resistant gram-positive infections. Expert Opin Pharmacother. 14, 1919 (2013). https://doi.org/10.1517/14656566.2013.820276
  4. O'Connell, K. M., Hodgkinson, J. T., Sore, H. F., Welch, M., Salmond, G. P. and Spring, D. R. : Combating multidrugresistant bacteria: Current strategies for the discovery of novel antibacterials. Angew. Chem. Int. Ed. Engl. 41, 10706 (2013).
  5. Pucci, M. J. and Bush, K. : Investigational antimicrobial agents of 2013. Clin. Microbiol. Rev. 26, 792 (2013). https://doi.org/10.1128/CMR.00033-13
  6. Perry, C. M. and Jarvis, B. : Linezolid: a review of its use in the management of serious Gram-positive infections. Drugs 61, 525 (2001). https://doi.org/10.2165/00003495-200161040-00008
  7. Flamm, R. K., Mendes, R. E., Ross, J. E., Sader, H. S. and Jones, R. N. : Linezolid surveillance results for the united states: LEADER surveillance program 2011. Antimicrob. Agents Chemother. 57, 1077 (2013). https://doi.org/10.1128/AAC.02112-12
  8. Gill, C. J., Abruzzo, G. K., Flattery, A. M., Misura, A. S., Bartizal, K. and Hickey, E. J. : In vivo efficacy of a novel oxazolidinone compound in two mouse models of infection. Antimicrob. Agents Chemother. 51, 3434 (2007). https://doi.org/10.1128/AAC.01567-06
  9. Leach, K. L., Swaney, S. M., Colca, J. R., McDonald, W. G., Blinn, J. R., Thomasco, L. M., Gadwood, R. C., Shinabarger, D., Siong, L. and Mankin, A. S. : The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol. Cell. 26, 393 (2007). https://doi.org/10.1016/j.molcel.2007.04.005
  10. Bing, G., Theodoros, K., Sotirios, T., Janet, H. and Romney, M. H. : The emerging problem of linezolid-resistant Staphylococcus. J. Antimicrob. Chemother. 68, 4 (2013). https://doi.org/10.1093/jac/dks354
  11. Meka, V. G. and Gold, H. S. : Antimicrobial resistance to linezolid. Clin. Infect. Dis. 39, 1010 (2004). https://doi.org/10.1086/423841
  12. Cattaneo, D., Orlando, G., Cozzi, V., Cordier, L., Baldelli, S., Merli, S., Fucile, S., Gulisano, C., Rizzardini, G. and Clementi, E. : Linezolid plasma concentrations and occurrence of drugrelated haematological toxicity in patients with gram-positive infections. Int. J. Antimicrob. Agents. 41, 586 (2013). https://doi.org/10.1016/j.ijantimicag.2013.02.020
  13. Nukui, Y., Hatakeyama, S., Okamoto, K., Yamamoto, T., Hisaka, A., Suzuki, H., Yata, N., Yotsuyanagi, H. and Moriya, K. : High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J. Antimicrob. Chemother. 68, 2128 (2013). https://doi.org/10.1093/jac/dkt133
  14. Jeong, J. W., Jung, S. J., Lee, H. H., Kim, Y. Z., Park, T. K., Cho, Y. L., Chae, S. E., Baek, S. Y., Woo, S. H., Lee, H. S. and Kwak, J. H. : In vitro and in vivo activities of LCB01-0371, a new oxazolidinone. Antimicrob. Agents Chemother. 54, 5359 (2010). https://doi.org/10.1128/AAC.00723-10
  15. Jones, R. N., Moet, G. J., Sader, H. S., Mendes, R. E. and Castanheira, M. : TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens. J. Antimicrob. Chemother. 63, 716 (2009). https://doi.org/10.1093/jac/dkp021
  16. Prystowsky, J., Siddiqui, F., Chosay, J., Shinabarger, D. L., Millichap, J., Peterson, L. R. and Noskin, G. A. : Resistance to linezolid : characterization of mutations in rRNA and comparison of their occurrences. Antimicrob. Agents Chemother. 45, 2154 (2001). https://doi.org/10.1128/AAC.45.7.2154-2156.2001
  17. Samir, N. P., Nader, M., Dea, S., Baldwin, T., Frances, B. J. and David, J. F. : Linezolid resistance in Enterococcus faecium isolated in Ontario, Canada. Diagn. Microbiol. Infect. Dis. 77, 350 (2013). https://doi.org/10.1016/j.diagmicrobio.2013.08.012
  18. Lobritz, M., Hutton-Thomas, R., Marshall, S. and Rice, L. B. : Recombination proficiency influences frequency and locus of mutational resistance to linezolid in Enterococcus faecalis. Antimicrob. Agents Chemother. 47, 3318 (2003). https://doi.org/10.1128/AAC.47.10.3318-3320.2003